vs
STANDARD BIOTOOLS INC.（LAB）与SuperCom Ltd（SPCB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是SuperCom Ltd的1.4倍（$19.6M vs $14.2M），SuperCom Ltd净利率更高（37.5% vs -177.4%，领先214.9%），SuperCom Ltd同比增速更快（-1.5% vs -11.5%），SuperCom Ltd自由现金流更多（$-3.6M vs $-23.1M）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
Super.com是一家总部位于美国旧金山的科技公司，由侯赛因·法扎勒和施亨利联合创立。该公司主营金融服务业务，具体涵盖会员奖励计划以及旅行预订等相关服务，在出行与消费金融领域深耕发展。
LAB vs SPCB — 直观对比
营收规模更大
LAB
是对方的1.4倍
$14.2M
营收增速更快
SPCB
高出10.0%
-11.5%
净利率更高
SPCB
高出214.9%
-177.4%
自由现金流更多
SPCB
多$19.5M
$-23.1M
损益表 — Q3 FY2025 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $14.2M |
| 净利润 | $-34.7M | $5.3M |
| 毛利率 | 48.5% | 61.2% |
| 营业利润率 | -168.5% | 16.3% |
| 净利率 | -177.4% | 37.5% |
| 营收同比 | -11.5% | -1.5% |
| 净利润同比 | -28.8% | 79.5% |
| 每股收益（稀释后） | $-0.09 | $1.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABSPCB
| Q3 25 | $19.6M | — | ||
| Q2 25 | $21.8M | $14.2M | ||
| Q1 25 | $40.8M | — | ||
| Q3 24 | $22.1M | — | ||
| Q2 24 | $22.5M | $14.4M | ||
| Q1 24 | $45.5M | — | ||
| Q4 23 | $28.2M | — | ||
| Q3 23 | $25.4M | — |
净利润LABSPCB
| Q3 25 | $-34.7M | — | ||
| Q2 25 | $-33.5M | $5.3M | ||
| Q1 25 | $-26.0M | — | ||
| Q3 24 | $-26.9M | — | ||
| Q2 24 | $-45.7M | $3.0M | ||
| Q1 24 | $-32.2M | — | ||
| Q4 23 | $-19.8M | — | ||
| Q3 23 | $-21.0M | — |
毛利率LABSPCB
| Q3 25 | 48.5% | — | ||
| Q2 25 | 48.8% | 61.2% | ||
| Q1 25 | 48.4% | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | 46.1% | 52.3% | ||
| Q1 24 | 53.1% | — | ||
| Q4 23 | 47.6% | — | ||
| Q3 23 | 44.0% | — |
营业利润率LABSPCB
| Q3 25 | -168.5% | — | ||
| Q2 25 | -118.1% | 16.3% | ||
| Q1 25 | -80.8% | — | ||
| Q3 24 | -120.9% | — | ||
| Q2 24 | -134.5% | 7.7% | ||
| Q1 24 | -132.2% | — | ||
| Q4 23 | -75.9% | — | ||
| Q3 23 | -83.5% | — |
净利率LABSPCB
| Q3 25 | -177.4% | — | ||
| Q2 25 | -153.7% | 37.5% | ||
| Q1 25 | -63.8% | — | ||
| Q3 24 | -122.0% | — | ||
| Q2 24 | -203.3% | 20.6% | ||
| Q1 24 | -70.6% | — | ||
| Q4 23 | -70.2% | — | ||
| Q3 23 | -82.8% | — |
每股收益（稀释后）LABSPCB
| Q3 25 | $-0.09 | — | ||
| Q2 25 | $-0.09 | $1.32 | ||
| Q1 25 | $-0.07 | — | ||
| Q3 24 | $-0.07 | — | ||
| Q2 24 | $-0.12 | $1.19 | ||
| Q1 24 | $-0.27 | — | ||
| Q4 23 | $-0.24 | — | ||
| Q3 23 | $-0.27 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $15.0M |
| 总债务越低越好 | — | $23.6M |
| 股东权益账面价值 | $399.7M | $37.3M |
| 总资产 | $539.6M | $65.5M |
| 负债/权益比越低杠杆越低 | — | 0.63× |
8季度趋势，按日历期对齐
现金及短期投资LABSPCB
| Q3 25 | $129.4M | — | ||
| Q2 25 | $158.6M | $15.0M | ||
| Q1 25 | $150.9M | — | ||
| Q3 24 | $210.6M | — | ||
| Q2 24 | $269.8M | $5.7M | ||
| Q1 24 | $287.1M | — | ||
| Q4 23 | $51.7M | — | ||
| Q3 23 | $79.7M | — |
总债务LABSPCB
| Q3 25 | — | — | ||
| Q2 25 | — | $23.6M | ||
| Q1 25 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | $29.2M | ||
| Q1 24 | $55.0M | — | ||
| Q4 23 | $63.5M | — | ||
| Q3 23 | $64.6M | — |
股东权益LABSPCB
| Q3 25 | $399.7M | — | ||
| Q2 25 | $424.5M | $37.3M | ||
| Q1 25 | $454.6M | — | ||
| Q3 24 | $489.3M | — | ||
| Q2 24 | $510.3M | $13.8M | ||
| Q1 24 | $577.3M | — | ||
| Q4 23 | $-148.1M | — | ||
| Q3 23 | $-131.7M | — |
总资产LABSPCB
| Q3 25 | $539.6M | — | ||
| Q2 25 | $557.0M | $65.5M | ||
| Q1 25 | $579.6M | — | ||
| Q3 24 | $681.5M | — | ||
| Q2 24 | $708.7M | $49.6M | ||
| Q1 24 | $777.7M | — | ||
| Q4 23 | $323.1M | — | ||
| Q3 23 | $339.3M | — |
负债/权益比LABSPCB
| Q3 25 | — | — | ||
| Q2 25 | — | 0.63× | ||
| Q1 25 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | 2.11× | ||
| Q1 24 | 0.10× | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $-2.2M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $-3.6M |
| 自由现金流率自由现金流/营收 | -118.1% | -25.3% |
| 资本支出强度资本支出/营收 | 4.5% | 10.0% |
| 现金转化率经营现金流/净利润 | — | -0.41× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $-14.0M |
8季度趋势，按日历期对齐
经营现金流LABSPCB
| Q3 25 | $-22.2M | — | ||
| Q2 25 | $-20.7M | $-2.2M | ||
| Q1 25 | $-30.3M | — | ||
| Q3 24 | $-27.9M | — | ||
| Q2 24 | $-39.0M | $-950.0K | ||
| Q1 24 | $-62.5M | — | ||
| Q4 23 | $-14.1M | — | ||
| Q3 23 | $-11.4M | — |
自由现金流LABSPCB
| Q3 25 | $-23.1M | — | ||
| Q2 25 | $-22.6M | $-3.6M | ||
| Q1 25 | $-35.3M | — | ||
| Q3 24 | $-30.1M | — | ||
| Q2 24 | $-41.0M | $-1.6M | ||
| Q1 24 | $-63.3M | — | ||
| Q4 23 | $-14.1M | — | ||
| Q3 23 | $-12.3M | — |
自由现金流率LABSPCB
| Q3 25 | -118.1% | — | ||
| Q2 25 | -103.6% | -25.3% | ||
| Q1 25 | -86.6% | — | ||
| Q3 24 | -136.4% | — | ||
| Q2 24 | -182.2% | -10.8% | ||
| Q1 24 | -138.9% | — | ||
| Q4 23 | -50.2% | — | ||
| Q3 23 | -48.6% | — |
资本支出强度LABSPCB
| Q3 25 | 4.5% | — | ||
| Q2 25 | 8.7% | 10.0% | ||
| Q1 25 | 12.4% | — | ||
| Q3 24 | 10.2% | — | ||
| Q2 24 | 8.6% | 4.2% | ||
| Q1 24 | 1.7% | — | ||
| Q4 23 | 0.3% | — | ||
| Q3 23 | 3.6% | — |
现金转化率LABSPCB
| Q3 25 | — | — | ||
| Q2 25 | — | -0.41× | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.32× | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
SPCB
暂无分部数据
